GlassScriptPhysician profile
Paul T Joyce
NPI 1417048166
$2,936.50
in general payments reported to CMS, 2019-2025
13 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $616 · 2023: $711 · 2024: $918 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,241.10 | 2021-2025 | Collagenase Santyl, Renasys Go V2 Home, Iodosorb Ointment 40g USA |
| Organogenesis INC. | $434.29 | 2021-2024 | Puraply, Puraply Am |
| Bioventus LLC | $418.36 | 2021-2023 | |
| Reprise Biomedical, INC. | $335.51 | 2024-2025 | Miro3d |
| Paratek Pharmaceuticals, INC. | $218.15 | 2022-2025 | Nuzyra |
| Solventum Corporation | $90.61 | 2024 | Activ.A.C., Promogran Prisma, V.A.C. Dermatac |
| Hydrofera LLC | $52.57 | 2022 | |
| Urgo Medical North America, LLC | $49.45 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Kci USA, INC. | $24.43 | 2023 | Promogran Prisma, V.A.C. Dermatac |
| Advanced Oxygen Therapy INC. | $20.34 | 2025 | Topical Oxygen Chamber For Extremities |
| Reddress USA, INC. | $18.46 | 2024 | |
| Misonix INC | $17.11 | 2021 | |
| Mimedx Group, INC. | $16.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.